OCA
VIR icon

Octagon Capital Advisors’s Vir Biotechnology VIR Stock Holding History

Octagon Capital Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-325,050
Closed -$3.05M – 47
2023
Q3 		$3.05M Sell
325,050
-325,050
-50% -$4.64M 0.47% 33
2023
Q2 		$15.9M Buy
+650,100
New +$16.3M 2.22% 12

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Octagon Capital Advisors's VIR Position: Q4 2023 in Review

Octagon Capital Advisors sold out of Vir Biotechnology (VIR) in Q4 2023, closing a stake of 325,050 shares — an estimated $3.05M sold.

Octagon Capital Advisors first reported a position in VIR in Q2 2023 and held it in 2 quarters. The position peaked at $15.9M in Q2 2023. 206 funds tracked by Wall St. Rank hold VIR as of Q4 2023.

  • Octagon Capital Advisors reported no remaining Vir Biotechnology position as of Q4 2023 after selling out during the quarter.
  • Octagon Capital Advisors sold 325,050 Vir Biotechnology shares in Q4 2023, an estimated $3.05M.
  • Octagon Capital Advisors first reported a position in Vir Biotechnology in Q2 2023 and held it in 2 quarters.
  • Octagon Capital Advisors's Vir Biotechnology position peaked at $15.9M in Q2 2023.
  • 206 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2023.

Based on Octagon Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.